05 February 2024:  ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides the following update in relation to its current business development, financing discussions and working capital position.

Read more…

 

08 November 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell derived Exosome Technologies, announces its unaudited interim results for the six months ended 30 September 2023.

Read more…

In vivo data highlights the specific tissue and cellular targeting capabilities of ReNeuron’s stem cell derived exosome drug delivery platform, CustomEXTM

08 November 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that Dr Samantha Thomas will be presenting in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of ReNeuron’s CustomEX™ drug delivery platform, at Cell 2023 in London.

Read more…

Creating a valuable and differentiated Exosome Delivery Platform

04 September 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that it has successfully generated in vivo data to exemplify the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines. The Company will now look to broaden its capabilities and focus on the functional delivery of specific payloads.

Read more…

22 August 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.

Read more…

24 July 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that the Notice of Annual General Meeting (“AGM”) and Form of Proxy have today been posted to shareholders and will shortly be available on the investors section of the Company’s website.

Read more…

16 June 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that its Annual Report and Accounts for the year ended 31 March 2023 has today been sent to shareholders and is available to download on the Company’s website here: https://www.reneuron.com/investors/financial-reports/

 

Unaudited Preliminary Results for the year ended 31 March 2023

Creating a valuable and differentiated Drug Delivery Platform

25 May 2023:  ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces its unaudited preliminary results for the year ended 31 March 2023.

Read more…

18 May 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, will announce its preliminary results for the year ended 31 March 2023 on Thursday 25 May 2023.

Read more…

03 April 2023:  ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces the appointment of Prof. Giuseppe (Beppe) Battaglia, Prof. Edit I Buzás, Prof. Dr. rer. Nat. Bernd Giebel and Prof. Kenneth W. Witwer to a newly established Scientific Advisory Board (SAB), chaired by Prof. Stefano Pluchino.

Read more…